Stocks Health care TNXP
NASDAQ · Health careTonix Pharmaceuticals Holding Corp. (TNXP)
Tonix Pharmaceuticals Holding Corp. brought in $43M of revenue over the twelve months to September 30, 2026, up 318.0% from a year earlier. It posted a net loss of $181M. In fiscal 2025 capital spending exceeded operating cash flow by $103.2M. At September 30, 2026 it held $162.8M in cash. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on November 9, 2026.
Key facts about Tonix Pharmaceuticals Holding Corp.
- Net worth
- Tonix Pharmaceuticals Holding Corp. has a market value (market cap) of $77M at the latest share price, and shareholders' equity of $199.5M on its balance sheet at September 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
- Revenue and profit
- In fiscal 2025 revenue was $13.1M (+29.8% year on year), with a net loss of $124M. Over the 12 months to September 30, 2026: revenue $43M, net loss $181M.
- Cash flow
- In fiscal 2025 operations used $99.8M of cash.
- Latest report
- The latest periodic report (quarterly report, 10-Q) was filed with the SEC on November 9, 2026 and covers the period to September 30, 2026. Open on SEC EDGAR
- Next earnings report
- Tonix Pharmaceuticals Holding Corp.'s next report is expected around December 28, 2026. That is an estimate from its filing rhythm, not a date the company has announced.
What Tonix Pharmaceuticals Holding Corp. does
Tonix Pharmaceuticals Holding Corp. is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on NASDAQ under the ticker TNXP.
Revenue and profit by year
Key figures
| Fiscal year | Revenue | Net income | Diluted EPS | Free cash flow |
|---|---|---|---|---|
| 2025 | $13.1M | -$124M | -$14.57 | -$103.2M |
| 2024 | $10.1M | -$130M | -$176.60 | -$61M |
| 2023 | $7.8M | -$116.7M | -$14,720.25 | -$109.9M |
| 2022 | n/a | -$110.2M | -$43,000.32 | -$146.2M |
| 2021 | n/a | -$92.3M | -$106,514.56 | -$110.9M |
| 2020 | n/a | -$50.5M | -$225,319.26 | -$57.1M |
Earnings: every quarter and the next report date
Full financial statements: income, balance sheet and cash flow
Where TNXP ranks in Health care
Latest SEC filings
What Tonix Pharmaceuticals Holding Corp. has filed recently, newest first. Each links to the original document on SEC EDGAR.
- November 9, 2026Quarterly report 10-Q · period to September 30, 2026Revenue rose 424% to $17.2M versus the same quarter last year; diluted EPS -$2.89 versus -$3.59.
- November 9, 2026
- October 15, 2026
- October 2, 2026Other event 8-K
- September 22, 2026Other event 8-K
- September 8, 2026Other event 8-K
- August 18, 2026
- August 14, 2026Passive stake changed SCHEDULE 13G/A
- August 13, 2026Passive stake (5% or more) SCHEDULE 13G
- August 10, 2026Quarterly report 10-Q · period to June 30, 2026Revenue rose 578% to $13.5M versus the same quarter last year; diluted EPS -$2.44 versus -$3.86.
Insider trades
What the people running Tonix Pharmaceuticals Holding Corp. did with its shares, from the Form 4 filings they must send the SEC within two business days.
Insiders bought $40.2K worth of shares on the open market in the last 90 days and sold none.
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| August 27, 2026 | Lederman SethChief Executive Officer, Director | Boughtindirect | 2,000 | $27.6K |
| August 20, 2026 | Bagger Richard HDirector | Bought | 1,000 | $12.6K |
| June 30, 2026 | Saenger BradleyChief Financial Officer | Other change | 1,453 | $15.9K |
| June 12, 2026 | Taylor Carolyn E.Director | Bought | 1,415 | $14.9K |
| June 9, 2026 | Lederman SethChief Executive Officer, Director | Bought | 5,000 | $58.9K |
| June 8, 2026 | Stillwell Richard NewcombDirector | Bought | 5,000 | $58.3K |
| March 31, 2026 | Lederman SethChief Executive Officer, Director | Boughtindirect | 5,000 | $63.1K |
| March 18, 2026 | Lederman SethChief Executive Officer, Director | Boughtindirect | 15,000 | $223.4K |
Who owns TNXP
Three views from three kinds of SEC filings, each with its own date. They overlap and are not added up.
5% holders
| Holder | Of class | Filed |
|---|---|---|
| Point72 Asset Management, L.P.13G, passive with 2 related filers | 6.9% | May 15, 2026 |
| Millennium Management LLC13G, passive with 2 related filers | 5.6% | June 15, 2026 |
| AQR Capital Management, LLC13G, passive with 1 related filers | 5.54% | August 13, 2026 |
Largest institutional holders
Positions that investment managers reported on Form 13F for the quarter ended June 30, 2026, largest first, with the change on the quarter ended March 31, 2026. Managers file 13F up to 45 days after a quarter ends. 103 managers reported a position.
| Holder | Shares | Change on quarter |
|---|---|---|
| BlackRock, Inc. | 1,398,041 | +429,864 |
| Point72 Asset Management, L.P. | 1,166,752 | +1,041,338 |
| Millennium Management LLC | 966,932 | +747,259 |
| Aqr Capital Management LLC | 882,595 | +721,387 |
| Vanguard Capital Management LLC | 691,895 | +173,245 |
| Jones Hill Capital LP | 625,428 | +173,312 |
| Geode Capital Management, LLC | 395,260 | +81,969 |
| Ishara Investments LP | 338,250 | new |
| State Street Corp | 271,374 | +40,767 |
| UBS Group AG | 231,682 | +4 |
| Citadel Advisors LLC | 195,859 | -272,853 |
| Essex Investment Management Co LLC | 165,144 | new |
| Balyasny Asset Management L.P. | 132,591 | -180,491 |
| Northern Trust Corp | 120,386 | +20,252 |
| Nuveen, LLC | 117,447 | +22,886 |
| Vanguard Fiduciary Trust Co | 102,054 | +17,784 |
| Goldman Sachs Group Inc | 98,356 | +45,301 |
| Vanguard Portfolio Management LLC | 97,954 | +19,327 |
| Fmr LLC | 93,551 | +91,813 |
| Ieq Capital, LLC | 92,373 | +78,015 |
Insiders
5 insiders reported holding 29,997 shares in total, about $123K at the last price.
| Holder | Shares |
|---|---|
| Lederman SethChief Executive Officer, Director | 20,01011,005 held indirectly |
| Stillwell Richard NewcombDirector | 5,000 |
| Saenger BradleyChief Financial Officer | 2,154 |
| Taylor Carolyn E.Director | 1,833 |
| Bagger Richard HDirector | 1,000 |
Questions about TNXP
What does Tonix Pharmaceuticals Holding Corp. do?
Tonix Pharmaceuticals Holding Corp. is a company in the Health care sector, listed on NASDAQ as TNXP. Its shares trade on NASDAQ under the ticker TNXP.
What is Tonix Pharmaceuticals Holding Corp.'s net worth?
Tonix Pharmaceuticals Holding Corp. has a market value (market cap) of $77M at the latest share price, and shareholders' equity of $199.5M on its balance sheet at September 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
Is Tonix Pharmaceuticals Holding Corp. profitable?
No. Over the twelve months to September 30, 2026 it reported a net loss of $181M on revenue of $43M.
How much revenue does Tonix Pharmaceuticals Holding Corp. make?
Over the twelve months to September 30, 2026 Tonix Pharmaceuticals Holding Corp. reported revenue of $43M. That is 318.0% more than a year earlier.
When did Tonix Pharmaceuticals Holding Corp. last report?
Its most recent periodic report is the quarterly report (10-Q) filed on November 9, 2026. It covers the period to September 30, 2026.
When is Tonix Pharmaceuticals Holding Corp.'s next earnings report?
Tonix Pharmaceuticals Holding Corp.'s next report is expected around December 28, 2026. That is an estimate from its filing rhythm, not a date the company has announced.
Similar companies
Compare TNXP with
Follow TNXP
Get an email when Tonix Pharmaceuticals Holding Corp. files with the SEC: results, executive changes, material agreements and annual reports.
Where the numbers come from
Financial figures are the values Tonix Pharmaceuticals Holding Corp. tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.